Drugs that contain Mirabegron
1. List of Myrbetriq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(10 months ago) | |
| US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(9 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6346532
(Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(4 months ago) | |
| USRE44872 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(9 months from now) | |
| US8835474 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(9 months from now) | |
| US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(9 months from now) | |
|
US8835474
(Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(1 year, 3 months from now) | |
|
US7342117
(Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 3 months from now) | |
|
US7982049
(Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 3 months from now) | |
|
USRE44872
(Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(1 year, 3 months from now) | |
| US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(5 years from now) | |
|
US8772315
(Pediatric) | APGDI | Pharmaceutical composition for treating overactive bladder |
Apr, 2029
(6 years from now) | |
| US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(6 years from now) | |
|
US10842780
(Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Mar 25, 2024 |
| Pediatric Exclusivity (PED) | Sep 25, 2024 |
Market Authorisation Date: 28 June, 2012
Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Use in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Administration of an extended release tablet for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
2. List of Myrbetriq Granules drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(10 months ago) | |
| US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(9 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6346532
(Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(4 months ago) | |
| US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(9 months from now) | |
|
US7342117
(Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 3 months from now) | |
|
US7982049
(Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 3 months from now) | |
| US10058536 | APGDI | Pharmaceutical composition containing mirabegron |
Mar, 2036
(13 years from now) | |
|
US10058536
(Pediatric) | APGDI | Pharmaceutical composition containing mirabegron |
Oct, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 25, 2024 |
| Pediatric Exclusivity (PED) | Sep 25, 2024 |
Market Authorisation Date: 25 March, 2021
Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic